  The accumulation of emergent This biomarker analysis of the global phase III ASPECCT study used next-generation sequencing to detect expanded Among panitumumab-treated patients with evaluable plasma samples at baseline ( n = 238) , 188 ( 79 %) were wild-type ( WT) Although patients with baseline ctDNA